L-type amino acid transport and cancer: Targeting the mTORC1 pathway to inhibit neoplasia

American Journal of Cancer Research

Volumn 5, Issue 4, 2015, Pages 1281-1294

  Wang, Qian ^a,b   Holst, Jeff ^a,b  

^a CENTENARY INSTITUTE   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Cancer; L type amino acid; mtorc1 pathway; Transport

Indexed keywords

2 AMINO 3 [4 [(5 AMINO 2 PHENYLBENZO[D]OXAZOL 7 YL)METHOXY] 3,5 DICHLOROPHENYL]PROPANOIC ACID; ACIVICIN; AMINO ACID TRANSPORTER; ANTINEOPLASTIC AGENT; ESK 242; ESK 246; GLYCOSIDE; IODOTYROSINE; L TYPE AMINO ACID TRANSPORT 1; L TYPE AMINO ACID TRANSPORT 2; L TYPE AMINO ACID TRANSPORT 3; L TYPE AMINO ACID TRANSPORT 4; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; UNCLASSIFIED DRUG;

DRUG MECHANISM; DRUG STRUCTURE; DRUG TARGETING; HUMAN; METASTASIS; MOLECULAR PATHOLOGY; NEOPLASM; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; REVIEW; SIGNAL TRANSDUCTION; STRUCTURE ANALYSIS;

EID: 85006216312     PISSN: None     EISSN: 21566976     Source Type: Journal    
DOI: None     Document Type: Review

References (118)

1. Kruczek K, Ratterman M, Tolzien K, Sulo S, Lestingi TM and Nabhan C. A phase II study evaluating the toxicity and efficacy of single-agent temsirolimus in chemotherapy-naive castration-resistant prostate cancer. Br J Cancer 2013; 109: 1711-1716.
2. Templeton AJ, Dutoit V, Cathomas R, Rothermundt C, Bartschi D, Droge C, Gautschi O, Borner M, Fechter E, Stenner F, Winterhalder R, Muller B, Schiess R, Wild PJ, Ruschoff JH, Thalmann G, Dietrich PY, Aebersold R, Klingbiel D, Gillessen S Swiss Group for Clinical Cancer Research (SAKK). Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08). Eur Urol 2013; 64: 150-158.
3. Fotiadis D, Kanai Y and Palacin M. The SLC3 and SLC7 families of amino acid transporters. Mol Aspects Med 2013; 34: 139-158.
4. Bodoy S, Fotiadis D, Stoeger C, Kanai Y and Palacin M. The small SLC43 family: facilitator system l amino acid transporters and the orphan EEG1. Mol Aspects Med 2013; 34: 638-645.
5. Kanai Y, Segawa H, Miyamoto K, Uchino H, Takeda E and Endou H. Expression cloning and characterization of a transporter for large neutral amino acids activated by the heavy chain of 4F2 antigen (CD98). J Biol Chem 1998; 273: 23629-23632.
6. Mastroberardino L, Spindler B, Pfeiffer R, Skelly PJ, Loffing J, Shoemaker CB and Verrey F. Amino-acid transport by heterodimers of 4F2hc/CD98 and members of a permease family. Nature 1998; 395: 288-291.
7. Pineda M, Fernandez E, Torrents D, Estevez R, Lopez C, Camps M, Lloberas J, Zorzano A and Palacin M. Identification of a membrane protein, LAT-2, that co-expresses with 4F2 heavy chain, an L-type amino acid transport activity with broad specificity for small and large zwitterionic amino acids. J Biol Chem 1999; 274: 19738-19744.
8. Rossier G, Meier C, Bauch C, Summa V, Sordat B, Verrey F and Kuhn LC. LAT2, a new basolateral 4F2hc/CD98-associated amino acid transporter of kidney and intestine. J Biol Chem 1999; 274: 34948-34954.
9. Segawa H, Fukasawa Y, Miyamoto K, Takeda E, Endou H and Kanai Y. Identification and functional characterization of a Na+-independent neutral amino acid transporter with broad substrate selectivity. J Biol Chem 1999; 274: 19745-19751.
10. Babu E, Kanai Y, Chairoungdua A, Kim DK, Iribe Y, Tangtrongsup S, Jutabha P, Li Y, Ahmed N, Sakamoto S, Anzai N, Nagamori S and Endou H. Identification of a novel system L amino acid transporter structurally distinct from heterodimeric amino acid transporters. J Biol Chem 2003; 278: 43838-43845.
11. Bodoy S, Martin L, Zorzano A, Palacin M, Estevez R and Bertran J. Identification of LAT4, a novel amino acid transporter with system L activity. J Biol Chem 2005; 280: 12002-12011.
12. Park SY, Kim JK, Kim IJ, Choi BK, Jung KY, Lee S, Park KJ, Chairoungdua A, Kanai Y, Endou H and Kim DK. Reabsorption of neutral amino acids mediated by amino acid transporter LAT2 and TAT1 in the basolateral membrane of proximal tubule. Arch Pharm Res 2005; 28: 421-432.
13. Nicklin P, Bergman P, Zhang B, Triantafellow E, Wang H, Nyfeler B, Yang H, Hild M, Kung C, Wilson C, Myer VE, MacKeigan JP, Porter JA, Wang YK, Cantley LC, Finan PM and Murphy LO. Bidirectional transport of amino acids regulates mTOR and autophagy. Cell 2009; 136: 521-534.
14. Fuchs BC and Bode BP. Amino acid transporters ASCT2 and LAT1 in cancer: partners in crime? Semin Cancer Biol 2005; 15: 254-266.
15. Wang Q, Beaumont KA, Otte NJ, Font J, Bailey CG, van Geldermalsen M, Sharp DM, Tiffen JC, Ryan RM, Jormakka M, Haass NK, Rasko JE and Holst J. Targeting glutamine transport to suppress melanoma cell growth. Int J Cancer 2014; 135: 1060-1071.
16. Wang Q, Hardie RA, Hoy AJ, van Geldermalsen M, Gao D, Fazli L, Sadowski MC, Balaban S, Schreuder M, Nagarajah R, Wong JJ, Metierre C, Pinello N, Otte NJ, Lehman ML, Gleave M, Nelson CC, Bailey CG, Ritchie W, Rasko JE and Holst J. Targeting ASCT2-mediated glutamine uptake blocks prostate cancer growth and tumour development. J Pathol 2015; [Epub ahead of print].
17. Chuaqui RF, Englert CR, Strup SE, Vocke CD, Zhuang Z, Duray PH, Bostwick DG, Linehan WM, Liotta LA and Emmert-Buck MR. Identification of a novel transcript up-regulated in a clinically aggressive prostate carcinoma. Urology 1997; 50: 302-307.
18. Cole KA, Chuaqui RF, Katz K, Pack S, Zhuang Z, Cole CE, Lyne JC, Linehan WM, Liotta LA and Emmert-Buck MR. cDNA sequencing and analysis of POV1 (PB39): a novel gene up-regulated in prostate cancer. Genomics 1998; 51: 282-287.
19. Fukuhara D, Kanai Y, Chairoungdua A, Babu E, Bessho F, Kawano T, Akimoto Y, Endou H and Yan K. Protein characterization of NA+-independent system L amino acid transporter 3 in mice: a potential role in supply of branched-chain amino acids under nutrient starvation. Am J Pathol 2007; 170: 888-898.
20. Sekine Y, Nishibori Y, Akimoto Y, Kudo A, Ito N, Fukuhara D, Kurayama R, Higashihara E, Babu E, Kanai Y, Asanuma K, Nagata M, Majumdar A, Tryggvason K and Yan K. Amino acid transporter LAT3 is required for podocyte development and function. J Am Soc Nephrol 2009; 20: 1586-1596.
21. Chung J, Bauer DE, Ghamari A, Nizzi CP, Deck KM, Kingsley PD, Yien YY, Huston NC, Chen C, Schultz IJ, Dalton AJ, Wittig JG, Palis J, Orkin SH, Lodish HF, Eisenstein RS, Cantor AB and Paw BH. The mTORC1/4E-BP pathway coordinates hemoglobin production with L-leucine availability. Sci Signal 2015; 8: ra34.
22. Guetg A, Mariotta L, Bock L, Herzog B, Fingerhut R, Camargo SM and Verrey F. Essential amino acid transporter Lat4 (Slc43a2) is required for mouse development. J Physiol 2015; 593: 1273-89.
23. Pritchard C, Mecham B, Dumpit R, Coleman I, Bhattacharjee M, Chen Q, Sikes RA and Nelson PS. Conserved gene expression programs intesgrate mammalian prostate development and tumorigenesis. Cancer Res 2009; 69: 1739-1747.
24. Wang Q, Bailey CG, Ng C, Tiffen J, Thoeng A, Minhas V, Lehman ML, Hendy SC, Buchanan G, Nelson CC, Rasko JE and Holst J. Androgen receptor and nutrient signaling pathways coordinate the demand for increased amino acid transport during prostate cancer progression. Cancer Res 2011; 71: 7525-7536.
25. Wang Q, Tiffen J, Bailey CG, Lehman ML, Ritchie W, Fazli L, Metierre C, Feng YJ, Li E, Gleave M, Buchanan G, Nelson CC, Rasko JE and Holst J. Targeting amino acid transport in metastatic castration-resistant prostate cancer: effects on cell cycle, cell growth, and tumor development. J Natl Cancer Inst 2013; 105: 1463-1473.
26. Kaira K, Oriuchi N, Imai H, Shimizu K, Yanagitani N, Sunaga N, Hisada T, Tanaka S, Ishizuka T, Kanai Y, Endou H, Nakajima T and Mori M. Prognostic significance of L-type amino acid transporter 1 expression in resectable stage I-III nonsmall cell lung cancer. Br J Cancer 2008; 98: 742-748.
27. Kaira K, Oriuchi N, Imai H, Shimizu K, Yanagitani N, Sunaga N, Hisada T, Kawashima O, Iijima H, Ishizuka T, Kanai Y, Endou H, Nakajima T and Mori M. Expression of L-type amino acid transporter 1 (LAT1) in neuroendocrine tumors of the lung. Pathol Res Pract 2008; 204: 553-561.
28. Kaira K, Oriuchi N, Takahashi T, Nakagawa K, Ohde Y, Okumura T, Murakami H, Shukuya T, Kenmotsu H, Naito T, Kanai Y, Endo M, Kondo H, Nakajima T and Yamamoto N. L-type amino acid transporter 1 (LAT1) expression in malignant pleural mesothelioma. Anticancer Res 2011; 31: 4075-4082.
29. Kaira K, Oriuchi N, Imai H, Shimizu K, Yanagitani N, Sunaga N, Hisada T, Ishizuka T, Kanai Y, Endou H, Nakajima T and Mori M. L-Type Amino Acid Transporter 1 (LAT1) Is Frequently Expressed in Thymic Carcinomas but Is Absent in Thymomas. J Surg Oncol 2009; 99: 433-438.
30. Kobayashi K, Ohnishi A, Promsuk J, Shimizu S, Kanai Y, Shiokawa Y and Nagane M. Enhanced tumor growth elicited by L-type amino acid transporter 1 in human malignant glioma cells. Neurosurgery 2008; 62: 493-503; discussion 503-494.
31. Toyoda M, Kaira K, Ohshima Y, Ishioka NS, Shino M, Sakakura K, Takayasu Y, Takahashi K, Tominaga H, Oriuchi N, Nagamori S, Kanai Y, Oyama T and Chikamatsu K. Prognostic significance of amino-acid transporter expression (LAT1, ASCT2, and xCT) in surgically resected tongue cancer. Br J Cancer 2014; 110: 2506-2513.
32. Kaira K, Sunose Y, Arakawa K, Ogawa T, Sunaga N, Shimizu K, Tominaga H, Oriuchi N, Itoh H, Nagamori S, Kanai Y, Segawa A, Furuya M, Mori M, Oyama T and Takeyoshi I. Prognostic significance of L-type amino-acid transporter 1 expression in surgically resected pancreatic cancer. Br J Cancer 2012; 107: 632-638.
33. Namikawa M, Kakizaki S, Kaira K, Tojima H, Yamazaki Y, Horiguchi N, Sato K, Oriuchi N, Tominaga H, Sunose Y, Nagamori S, Kanai Y, Oyama T, Takeyoshi I and Yamada M. Expression of amino acid transporters (LAT1, ASCT2 and xCT) as clinical significance in hepatocellular carcinoma. Hepatol Res 2014; [Epub ahead of print].
34. Kaira K, Oriuchi N, Imai H, Shimizu K, Yanagitani N, Sunaga N, Hisada T, Tanaka S, Ishizuka T, Kanai Y, Endou H, Nakajima T and Mori M. l-type amino acid transporter 1 and CD98 expression in primary and metastatic sites of human neoplasms. Cancer Sci 2008; 99: 2380-2386.
35. Imai H, Kaira K, Oriuchi N, Yanagitani N, Sunaga N, Ishizuka T, Kanai Y, Endou H, Nakajima T and Mori M. L-type amino acid transporter 1 expression is a prognostic marker in patients with surgically resected stage I non-small cell lung cancer. Histopathology 2009; 54: 804-813.
36. Ichinoe M, Mikami T, Yoshida T, Igawa I, Tsuruta T, Nakada N, Anzai N, Suzuki Y, Endou H and Okayasu I. High expression of L-type amino-acid transporter 1 (LAT1) in gastric carcinomas: comparison with non-cancerous lesions. Pathol Int 2011; 61: 281-289.
37. Kaira K, Oriuchi N, Imai H, Shimizu K, Yanagitani N, Sunaga N, Hisada T, Ishizuka T, Kanai Y, Endou H, Nakajima T and Mori M. Prognostic significance of L-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (CD98) expression in early stage squamous cell carcinoma of the lung. Cancer Sci 2009; 100: 248-254.
38. Kaira K, Toyoda M, Shino M, Sakakura K, Takahashi K, Tominaga H, Oriuchi N, Kanai Y, Oyama T and Chikamatsu K. Clinicopathological significance of L-type amino acid transporter 1 (LAT1) expression in patients with adenoid cystic carcinoma. Pathol Oncol Res 2013; 19: 649-656.
39. Sakata T, Ferdous G, Tsuruta T, Satoh T, Baba S, Muto T, Ueno A, Kanai Y, Endou H and Okayasu I. L-type amino-acid transporter 1 as a novel biomarker for high-grade malignancy in prostate cancer. Pathol Int 2009; 59: 7-18.
40. Bartlett JMS, Thomas J, Ross DT, Seitz RS, Ring BZ, Beck RA, Pedersen HC, Munro A, Kunkler IH, Campbell FM, Jack W, Kerr GR, Johnstone L, Cameron DA and Chetty U. Mammostrat (R) as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapy. Breast Cancer Res 2010; 12: R47.
41. Ring BZ, Seitz RS, Beck R, Shasteen WJ, Tarr SM, Cheang MC, Yoder BJ, Budd GT, Nielsen TO, Hicks DG, Estopinal NC and Ross DT. Novel prognostic immunohistochemical biomarker panel for estrogen receptor-positive breast cancer. J Clin Oncol 2006; 24: 3039-3047.
42. Kim CS, Cho SH, Chun HS, Lee SY, Endou H, Kanai Y and Kim do K. BCH, an inhibitor of system L amino acid transporters, induces apoptosis in cancer cells. Biol Pharm Bull 2008; 31: 1096-1100.
43. Chung J, Kuo CJ, Crabtree GR and Blenis J. Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinases. Cell 1992; 69: 1227-1236.
44. Hara K, Yonezawa K, Kozlowski MT, Sugimoto T, Andrabi K, Weng QP, Kasuga M, Nishimoto I and Avruch J. Regulation of eIF-4E BP1 phosphorylation by mTOR. J Biol Chem 1997; 272: 26457-26463.
45. Sarbassov DD, Ali SM, Kim DH, Guertin DA, Latek RR, Erdjument-Bromage H, Tempst P and Sabatini DM. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 2004; 14: 1296-1302.
46. Sarbassov DD, Guertin DA, Ali SM and Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005; 307: 1098-1101.
47. Jacinto E, Facchinetti V, Liu D, Soto N, Wei S, Jung SY, Huang Q, Qin J and Su B. SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell 2006; 127: 125-137.
48. Duran RV, Oppliger W, Robitaille AM, Heiserich L, Skendaj R, Gottlieb E and Hall MN. Glutaminolysis activates Rag-mTORC1 signaling. Mol Cell 2012; 47: 349-358.
49. Bai X, Ma D, Liu A, Shen X, Wang QJ, Liu Y and Jiang Y. Rheb activates mTOR by antagonizing its endogenous inhibitor, FKBP38. Science 2007; 318: 977-980.
50. Tee AR, Manning BD, Roux PP, Cantley LC and Blenis J. Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. Curr Biol 2003; 13: 1259-1268.
51. Zhang Y, Gao X, Saucedo LJ, Ru B, Edgar BA and Pan D. Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins. Nat Cell Biol 2003; 5: 578-581.
52. Demetriades C, Doumpas N and Teleman AA. Regulation of TORC1 in response to amino acid starvation via lysosomal recruitment of TSC2. Cell 2014; 156: 786-799.
53. Menon S, Dibble CC, Talbott G, Hoxhaj G, Valvezan AJ, Takahashi H, Cantley LC and Manning BD. Spatial control of the TSC complex integrates insulin and nutrient regulation of mTORC1 at the lysosome. Cell 2014; 156: 771-785.
54. Han JM, Jeong SJ, Park MC, Kim G, Kwon NH, Kim HK, Ha SH, Ryu SH and Kim S. Leucyl-tRNA synthetase is an intracellular leucine sensor for the mTORC1-signaling pathway. Cell 2012; 149: 410-424.
55. Bonfils G, Jaquenoud M, Bontron S, Ostrowicz C, Ungermann C and De Virgilio C. Leucyl-tRNA synthetase controls TORC1 via the EGO complex. Mol Cell 2012; 46: 105-110.
56. Sancak Y, Peterson TR, Shaul YD, Lindquist RA, Thoreen CC, Bar-Peled L and Sabatini DM. The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1. Science 2008; 320: 1496-1501.
57. Kim E, Goraksha-Hicks P, Li L, Neufeld TP and Guan KL. Regulation of TORC1 by Rag GTPases in nutrient response. Nat Cell Biol 2008; 10: 935-945.
58. Jewell JL, Kim YC, Russell RC, Yu FX, Park HW, Plouffe SW, Tagliabracci VS and Guan KL. Differential regulation of mTORC1 by leucine and glutamine. Science 2015; 347: 194-198.
59. Sener A and Malaisse WJ. L-leucine and a nonmetabolized analogue activate pancreatic islet glutamate dehydrogenase. Nature 1980; 288: 187-189.
60. Zoncu R, Bar-Peled L, Efeyan A, Wang S, Sancak Y and Sabatini DM. mTORC1 senses lysosomal amino acids through an inside-out mechanism that requires the vacuolar H(+)-ATPase. Science 2011; 334: 678-683.
61. Rebsamen M, Pochini L, Stasyk T, de Araujo ME, Galluccio M, Kandasamy RK, Snijder B, Fauster A, Rudashevskaya EL, Bruckner M, Scorzoni S, Filipek PA, Huber KV, Bigenzahn JW, Heinz LX, Kraft C, Bennett KL, Indiveri C, Huber LA and Superti-Furga G. SLC38A9 is a component of the lysosomal amino acid sensing machinery that controls mTORC1. Nature 2015; 519: 477-81.
62. Wang S, Tsun ZY, Wolfson RL, Shen K, Wyant GA, Plovanich ME, Yuan ED, Jones TD, Chantranupong L, Comb W, Wang T, Bar-Peled L, Zoncu R, Straub C, Kim C, Park J, Sabatini BL and Sabatini DM. Lysosomal amino acid transporter SLC38A9 signals arginine sufficiency to mTORC1. Science 2015; 347: 188-194.
63. Tsun ZY, Bar-Peled L, Chantranupong L, Zoncu R, Wang T, Kim C, Spooner E and Sabatini DM. The Folliculin Tumor Suppressor Is a GAP for the RagC/D GTPases That Signal Amino Acid Levels to mTORC1. Molecular Cell 2013; 52: 495-505.
64. Peng M, Yin N and Li MO. Sestrins Function as Guanine Nucleotide Dissociation Inhibitors for Rag GTPases to Control mTORC1 Signaling. Cell 2014; 159: 122-133.
65. Bar-Peled L, Chantranupong L, Cherniack AD, Chen WW, Ottina KA, Grabiner BC, Spear ED, Carter SL, Meyerson M and Sabatini DM. A Tumor suppressor complex with GAP activity for the Rag GTPases that signal amino acid sufficiency to mTORC1. Science 2013; 340: 1100-1106.
66. Janpipatkul K, Suksen K, Borwornpinyo S, Jearawiriyapaisarn N, Hongeng S, Piyachaturawat P and Chairoungdua A. Downregulation of LAT1 expression suppresses cholangiocarcinoma cell invasion and migration. Cell Signal 2014; 26: 1668-1679.
67. Kaira K, Oriuchi N, Imai H, Shimizu K, Yanagitani N, Sunaga N, Hisada T, Kawashima O, Kamide Y, Ishizuka T, Kanai Y, Nakajima T and Mori M. Prognostic significance of L-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (CD98) expression in surgically resectable stage III non-small cell lung cancer. Exp Ther Med 2010; 1: 799-808.
68. Fenczik CA, Sethi T, Ramos JW, Hughes PE and Ginsberg MH. Complementation of dominant suppression implicates CD98 in integrin activation. Nature 1997; 390: 81-85.
69. Kim SM and Hahn JH. CD98 activation increases surface expression and clusteringof beta1 integrins in MCF-7 cells through FAK/Src- and cytoskeleton-independent mechanisms. Exp Mol Med 2008; 40: 261-270.
70. Zent R, Fenczik CA, Calderwood DA, Liu S, Dellos M and Ginsberg MH. Class- and splice variant-specific association of CD98 with integrin beta cytoplasmic domains. J Biol Chem 2000; 275: 5059-5064.
71. Kolesnikova TV, Mannion BA, Berditchevski F and Hemler ME. Beta1 integrins show specific association with CD98 protein in low density membranes. BMC Biochem 2001; 2: 10.
72. Prager GW, Feral CC, Kim C, Han J and Ginsberg MH. CD98hc (SLC3A2) interaction with the integrin beta subunit cytoplasmic domain mediates adhesive signaling. J Biol Chem 2007; 282: 24477-24484.
73. Dever TE, Feng L, Wek RC, Cigan AM, Donahue TF and Hinnebusch AG. Phosphorylation of initiation factor 2 alpha by protein kinase GCN2 mediates gene-specific translational control of GCN4 in yeast. Cell 1992; 68: 585-596.
74. Harding HP, Zhang Y, Zeng H, Novoa I, Lu PD, Calfon M, Sadri N, Yun C, Popko B, Paules R, Stojdl DF, Bell JC, Hettmann T, Leiden JM and Ron D. An integrated stress response regulates amino acid metabolism and resistance to oxidative stress. Mol Cell 2003; 11: 619-633.
75. Ren P, Yue M, Xiao D, Xiu R, Gan L, Liu H and Qing G. ATF4 and N-Myc coordinate glutamine metabolism in MYCN-amplified neuroblastoma cells through ASCT2 activation. J Pathol 2015; 235: 90-100.
76. Sato H, Nomura S, Maebara K, Sato K, Tamba M and Bannai S. Transcriptional control of cystine/glutamate transporter gene by amino acid deprivation. Biochem Biophys Res Commun 2004; 325: 109-116.
77. Shennan DB, Thomson J, Gow IF, Travers MT and Barber MC. L-leucine transport in human breast cancer cells (MCF-7 and MDA-MB-231): kinetics, regulation by estrogen and molecular identity of the transporter. Biochim Biophys Acta 2004; 1664: 206-16.
78. Hamdi MM and Mutungi G. Dihydrotestosterone stimulates amino acid uptake and the expression of LAT2 in mouse skeletal muscle fibres through an ERK1/2-dependent mechan-ism. J Physiol 2011; 589: 3623-3640.
79. Luo X, Yin P, Reierstad S, Ishikawa H, Lin Z, Pavone ME, Zhao H, Marsh EE and Bulun SE. Progesterone and mifepristone regulate L-type amino acid transporter 2 and 4F2 heavy chain expression in uterine leiomyoma cells. J Clin Endocrinol Metab 2009; 94: 4533-4539.
80. Elorza A, Soro-Arnáiz I, Meléndez-Rodríguez F, Rodríguez-Vaello V, Marsboom G, de Cárcer G, Acosta-Iborra B, Albacete-Albacete L, Ordóñez A, Serrano-Oviedo L, Giménez-Bachs J, Vara-Vega A, Salinas A, Sánchez-Prieto R, Martín Del Río R, Sánchez-Madrid F, Malumbres M, Landázuri M and Aragonés J. HIF2α Acts as an mTORC1 Activator through the Amino Acid Carrier SLC7A5. Mol Cell 2012; 48: 681-91.
81. Sinclair LV, Rolf J, Emslie E, Shi YB, Taylor PM and Cantrell DA. Control of amino-acid transport by antigen receptors coordinates the metabolic reprogramming essential for T cell differentiation. Nat Immunol 2013; 14: 500-508.
82. Nii T, Segawa H, Taketani Y, Tani Y, Ohkido M, Kishida S, Ito M, Endou H, Kanai Y, Takeda E and Miyamoto K. Molecular events involved in up-regulating human Na+-independent neutral amino acid transporter LAT1 during T-cell activation. Biochem J 2001; 358: 693-704.
83. Hann SR and Eisenman RN. Proteins encoded by the human c-myc oncogene: differential expression in neoplastic cells. Mol Cell Biol 1984; 4: 2486-2497.
84. Dang CV. MYC on the path to cancer. Cell 2012; 149: 22-35.
85. Oda K, Hosoda N, Endo H, Saito K, Tsujihara K, Yamamura M, Sakata T, Anzai N, Wempe MF, Kanai Y and Endou H. L-type amino acid transporter 1 inhibitors inhibit tumor cell growth. Cancer Sci 2010; 101: 173-179.
86. Yun DW, Lee SA, Park MG, Kim JS, Yu SK, Park MR, Kim SG, Oh JS, Kim CS, Kim HJ, Kim JS, Chun HS, Kanai Y, Endou H, Wempe MF and Kim do K. JPH203, an L-type amino acid transporter 1-selective compound, induces apoptosis of YD-38 human oral cancer cells. J Pharmacol Sci 2014; 124: 208-217.
87. Rosilio C, Nebout M, Imbert V, Griessinger E, Neffati Z, Benadiba J, Hagenbeek T, Spits H, Reverso J, Ambrosetti D, Michiels JF, Bailly-Maitre B, Endou H, Wempe MF and Peyron JF. L-type amino acid transporter 1 (LAT1): a therapeutic target supporting growth and survival of t-cell lymphoblastic lymphoma/t-cell acute lymphoblastic leukemia. Leukemia 2014; [Epub ahead of print].
88. Wempe MF, Rice PJ, Lightner JW, Jutabha P, Hayashi M, Anzai N, Wakui S, Kusuhara H, Sugiyama Y and Endou H. Metabolism and pharmacokinetic studies of JPH203, an L-amino acid transporter 1 (LAT1) selective compound. Drug Metab Pharmacokinet 2012; 27: 155-161.
89. Toyoshima J, Kusuhara H, Wempe MF, Endou H and Sugiyama Y. Investigation of the role of transporters on the hepatic elimination of an LAT1 selective inhibitor JPH203. J Pharm Sci. 2013; 102: 3228-38.
90. Geier EG, Schlessinger A, Fan H, Gable JE, Irwin JJ, Sali A and Giacomini KM. Structure-based ligand discovery for the Large-neutral Amino Acid Transporter 1, LAT-1. Proc Natl Acad Sci U S A 2013; 110: 5480-5485.
91. Wang Q, Grkovic T, Font J, Bonham S, Pouwer RH, Bailey CG, Moran AM, Ryan RM, Rasko JE, Jormakka M, Quinn RJ and Holst J. Monoterpene glycoside ESK246 from Pittosporum targets LAT3 amino acid transport and prostate cancer cell growth. ACS Chem Biol 2014; 9: 1369-1376.
92. Eltz S, Comperat E, Cussenot O and Roupret M. Molecular and histological markers in urothelial carcinomas of the upper urinary tract. BJU Int 2008; 102: 532-535.
93. Kim DK, Kanai Y, Choi HW, Tangtrongsup S, Chairoungdua A, Babu E, Tachampa K, Anzai N, Iribe Y and Endou H. Characterization of the system L amino acid transporter in T24 human bladder carcinoma cells. Biochim Biophys Acta 2002; 1565: 112-121.
94. Baniasadi S, Chairoungdua A, Iribe Y, Kanai Y, Endou H, Aisaki K, Igarashi K and Kanno J. Gene expression profiles in T24 human bladder carcinoma cells by inhibiting an L-type amino acid transporter, LAT1. Arch Pharm Res 2007; 30: 444-452.
95. Furuya M, Horiguchi J, Nakajima H, Kanai Y and Oyama T. Correlation of L-type amino acid transporter 1 and CD98 expression with triple negative breast cancer prognosis. Cancer Sci 2012; 103: 382-389.
96. Shennan DB and Thomson J. Inhibition of system L (LAT1/CD98hc) reduces the growth of cultured human breast cancer cells. Oncol Rep 2008; 20: 885-889.
97. Shennan DB, Thomson J, Barber MC and Travers MT. Functional and molecular characteristics of system L in human breast cancer cells. Biochim Biophys Acta 2003; 1611: 81-90.
98. Uno K, Kuwabara H, Terado Y, Kojima K, Kawakami T, Kamma H, Sakurai H, Sakamoto A and Kurata A. Divergent expression of L-type amino acid transporter 1 during uterine cervical carcinogenesis. Hum Pathol 2011; 42: 1660-1666.
99. Haase C, Bergmann R, Fuechtner F, Hoepping A and Pietzsch J. L-type amino acid transporters LAT1 and LAT4 in cancer: uptake of 3-O-methyl-6-18F-fluoro-L-dopa in human adenocarcinoma and squamous cell carcinoma in vitro and in vivo. J Nucl Med 2007; 48: 2063-2071.
100. Kobayashi H, Ishii Y and Takayama T. Expression of L-type amino acid transporter 1 (LAT1) in esophageal carcinoma. J Surg Oncol 2005; 90: 233-238.
101. Yamauchi K, Sakurai H, Kimura T, Wiriyasermkul P, Nagamori S, Kanai Y and Kohno N. System L amino acid transporter inhibitor enhances anti-tumor activity of cisplatin in a head and neck squamous cell carcinoma cell line. Cancer Lett 2009; 276: 95-101.
102. Yanagida O, Kanai Y, Chairoungdua A, Kim DK, Segawa H, Nii T, Cha SH, Matsuo H, Fukushima J, Fukasawa Y, Tani Y, Taketani Y, Uchino H, Kim JY, Inatomi J, Okayasu I, Miyamoto K, Takeda E, Goya T and Endou H. Human L-type amino acid transporter 1 (LAT1): characterization of function and expression in tumor cell lines. Biochim Biophys Acta 2001; 1514: 291-302.
103. Xu SM, Tang K, Meng L and Tang Y. Suppression of amino acid transporter LAT3 expression on proliferation of K562 cells. J Huazhong Univ Sci Technolog Med Sci 2013; 33: 632-635.
104. Ohkame H, Masuda H, Ishii Y and Kanai Y. Expression of L-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (4F2hc) in liver tumor lesions of rat models. J Surg Oncol 2001; 78: 265-271; discussion 271-262.
105. Tamai S, Masuda H, Ishii Y, Suzuki S, Kanai Y and Endou H. Expression of L-type amino acid transporter 1 in a rat model of liver metastasis: positive correlation with tumor size. Cancer Detect Prev 2001; 25: 439-445.
106. Storey BT, Fugere C, Lesieur-Brooks A, Vaslet C and Thompson NL. Adenoviral modulation of the tumor-associated system L amino acid transporter, LAT1, alters amino acid transport, cell growth and 4F2/CD98 expressionwith cell-type specific effects in cultured hepatic cells. Int J Cancer 2005; 117: 387-397.
107. Kondoh N, Imazeki N, Arai M, Hada A, Hatsuse K, Matsuo H, Matsubara O, Ohkura S and Yamamoto M. Activation of a system A amino acid transporter, ATA1/SLC38A1, in human hepatocellular carcinoma and preneoplastic liver tissues. Int J Oncol 2007; 31: 81-87.
108. Ritchie JW and Taylor PM. Tryptophan and iodothyronine transport interactions in HepG2 human hepatoma cells. Amino Acids 2010; 38: 1361-1367.
109. Ochiai H, Morishita T, Onda K, Sugiyama H and Maruo T. Canine Lat1: molecular structure, distribution and its expression in cancer samples. J Vet Med Sci 2012; 74: 917-922.
110. Kuhne A, Kaiser R, Schirmer M, Heider U, Muhlke S, Niere W, Overbeck T, Hohloch K, Trumper L, Sezer O and Brockmoller J. Genetic polymorphisms in the amino acid transporters LAT1 and LAT2 in relation to the pharmacokinetics and side effects of melphalan. Pharmacogenet Genomics 2007; 17: 505-517.
111. Kuhne A, Tzvetkov MV, Hagos Y, Lage H, Burckhardt G and Brockmoller J. Influx and efflux transport as determinants of melphalan cytotoxicity: Resistance to melphalan in MDR1 overexpressing tumor cell lines. Biochemical Pharmacology 2009; 78: 45-53.
112. Isoda A, Kaira K, Iwashina M, Oriuchi N, Tominaga H, Nagamori S, Kanai Y, Oyama T, Asao T, Matsumoto M and Sawamura M. Expression of L-type amino acid transporter 1 (LAT1) as a prognostic and therapeutic indicator in multiple myeloma. Cancer Sci 2014; 105: 1496-1502.
113. Fan X, Ross DD, Arakawa H, Ganapathy V, Tamai I and Nakanishi T. Impact of system L amino acid transporter 1 (LAT1) on proliferation of human ovarian cancer cells: a possible target for combination therapy with anti-proliferative aminopeptidase inhibitors. Biochem Pharmacol 2010; 80: 811-818.
114. Kaji M, Kabir-Salmani M, Anzai N, Jin CJ, Akimoto Y, Horita A, Sakamoto A, Kanai Y, Sakurai H and Iwashita M. Properties of L-type amino acid transporter 1 in epidermal ovarian cancer. Int J Gynecol Cancer 2010; 20: 329-336.
115. Yanagisawa N, Ichinoe M, Mikami T, Nakada N, Hana K, Koizumi W, Endou H and Okayasu I. High expression of L-type amino acid transporter 1 (LAT1) predicts poor prognosis in pancreatic ductal adenocarcinomas. J Clin Pathol 2012; 65: 1019-1023.
116. Hayashi K, Jutabha P, Endou H and Anzai N. c-Myc is crucial for the expression of LAT1 in MIA Paca-2 human pancreatic cancer cells. Oncology Reports 2012; 28: 862-866.
117. Nakanishi K, Ogata S, Matsuo H, Kanai Y, Endou H, Hiroi S, Tominaga S, Aida S, Kasamatsu H and Kawai T. Expression of LAT1 predicts risk of progression of transitional cell carcinoma of the upper urinary tract. Virchows Arch 2007; 451: 681-690.
118. Luo X, Coon VJS, Su E, Pearson EK, Yin P, Ishikawa H and Bulun SE. LAT1 Regulates Growth of Uterine Leiomyoma Smooth Muscle Cells. Reprod Sci 2010; 17: 791-797.